learndrugs
Nervous

Myasthenia Gravis

MG Verified · Sep 2026

Myasthenia gravis (MG) is a chronic autoimmune disease — the most common disorder of the neuromuscular junction — in which antibodies block or destroy acetylcholine receptors on skeletal muscle, producing fluctuating weakness that worsens with activity and improves with rest.

The disorder behind the fatigable ptosis, the ice-pack test, the mandatory chest CT for thymoma, pyridostigmine given exactly on time about an hour before meals, the bedside FVC and NIF trend, and the myasthenic-versus-cholinergic crisis question that has one shared answer: airway first.

What’s going wrong in the body

The normal physiology, where it fails, and why the body’s compensation backfires.

01 The neuromuscular junction — and the antibody that jams it

Every voluntary contraction begins the same way: a nerve impulse releases acetylcholine (ACh) into the neuromuscular junction, ACh binds nicotinic receptors on the muscle end-plate, the fiber fires, and acetylcholinesterase then breaks ACh down into choline and acetic acid so the synapse can reset. MG is the most common disorder of that junction. In most patients the immune system makes anti-AChR antibodies — IgG1 and IgG3 — that injure the postsynaptic membrane by three mechanisms: they activate complement, forming the membrane attack complex that destroys the receptor-bearing folds; they functionally block ACh from binding; and they cross-link receptors and drive their endocytosis and degradation. It is a type II (antibody-mediated) hypersensitivity aimed at the postsynaptic membrane.

The consequence is the loss of the junction’s safety factor. With fewer functional receptors, the ACh released by a single impulse may not generate the end-plate potential needed to trigger a muscle action potential — and with repeated firing, ACh release falls and more fibers drop out. That is the whole clinical signature in one sentence: weakness that worsens with repetitive use and recovers with rest or sleep, classically worst in the afternoon and evening. Because the lesion sits at the junction rather than the nerve or the central nervous system, pupils, deep tendon reflexes, and sensation stay normal — the negative findings that separate MG from Guillain-Barré syndrome and multiple sclerosis.

A minority of patients carry different antibodies. Anti-MuSK (about 5–10%) and anti-LRP4 antibodies are IgG4, do not activate complement, and instead disrupt the agrin–LRP4–MuSK complex that clusters receptors on the end-plate. That molecular difference has bedside consequences: MuSK patients often respond poorly to pyridostigmine, gain nothing from thymectomy, and do better with plasma exchange and rituximab. Seronegative MG means no antibody on standard assays; more sensitive cell-based assays find AChR antibodies in some of these patients.

Normal transmission (top) and the three ways anti-AChR antibodies break it — complement destruction, functional block, and receptor endocytosis — converging on a lost safety factor and fatigable weakness.

02 The thymus — where self-tolerance is lost

The thymus is where the immune system learns self-tolerance, and in MG that lesson appears to fail. About 75% of patients have thymic disease: roughly two-thirds have thymic hyperplasia — epithelial hyperplasia with ectopic germinal centers, the histology of an organ manufacturing autoantibody — and about 10% have a thymoma. The association runs both ways: about 30–50% of thymoma patients have MG, making MG the most common autoimmune disorder linked to the thymus. MuSK-MG is the exception; its thymus shows only age-related change, which is one reason thymectomy is not offered to those patients. Anti-striational muscle antibodies, present in about 30% of MG patients, are chiefly useful as a thymoma marker.

Epidemiology follows a bimodal pattern that exams love: a female predominance under age 40 and a male predominance over age 50 — young women and older men. Guidelines split generalized disease into early-onset (< 50 years) and late-onset (≥ 50 years) subtypes, and manage thymoma-associated and MuSK/LRP4 disease differently. Prevalence is about 12–20 per 100,000. Autoimmunity clusters: about 10% of patients have another autoimmune condition, so baseline ANA, rheumatoid factor, and thyroid function tests are drawn at diagnosis.

03 Why the drug works — and why too much paralyzes

If the problem is too few working receptors, the symptomatic fix is more ACh for longer. Anticholinesterase drugs — pyridostigmine is preferred over neostigmine for its longer action — block acetylcholinesterase, raising both the level and the duration of action of ACh at the junction so the surviving receptors are stimulated more. Onset is about 15–30 minutes and the effect lasts about 3–4 hours, which is why the drug is dosed several times through the waking day, why it must be given exactly on time (a late dose means a weak patient), and why meals are timed to its peak. It is symptomatic only — it does not change the course of the disease; that is the job of corticosteroids, steroid-sparing immunosuppressants, thymectomy, and the rapid-acting rescues, IVIG and plasma exchange.

The same mechanism has a ceiling. ACh acts on muscarinic receptors too — glands, gut, heart, pupil — so excess drug produces hypersalivation, lacrimation, urination, diarrhea and cramping, emesis, miosis, bronchorrhea, bradycardia (the SLUDGEM / DUMBELS lists). At the nicotinic receptor, too much ACh causes fasciculation, then depolarization block, then flaccid weakness — including the respiratory muscles. That is cholinergic crisis: a weak patient made weaker by the treatment. It is rare with modern dosing, and it is clinically difficult to tell from a myasthenic crisis, which is why professional guidance manages both the same way rather than betting the airway on the distinction.

One drug, two receptor families: enough pyridostigmine restores strength; too much floods muscarinic receptors (secretions, bradycardia, miosis) and pushes nicotinic receptors into depolarization block — cholinergic crisis.

04 Ocular, generalized, and the road to crisis

Disease is classified by how far it has spread. Ocular MG (MGFA Class I) is any weakness of the eye muscles, including eye closure, with normal strength everywhere else. Generalized MG is weakness beyond the eyes: Class II mild, Class III moderate, Class IV severe, and Class V intubated with or without mechanical ventilation. Each class carries a subclass — a for predominantly limb or axial weakness, b for predominantly oropharyngeal and/or respiratory weakness. The b patient is the one whose swallow and breathing you watch. Ocular-onset disease generalizes in about 50% of patients within two years; in one retrospective series, 36% of untreated patients generalized versus only 7% of those on prednisone. Remissions happen but are rarely permanent, and weakness varies day to day.

The dangerous ending is myasthenic crisis — by the 2016 international consensus definition, worsening myasthenic weakness that requires intubation or noninvasive ventilation to avoid intubation. Impending crisis is rapid worsening that could reach that point within days to weeks. It touches 15–20% of patients at least once. Infection is a leading trigger — especially respiratory infection — followed by surgery, pregnancy and especially the postpartum months, tapering immunotherapy, heat, stress, aspiration, drugs that impair transmission, and starting high-dose corticosteroids; up to half cannot identify a trigger. Crisis mortality, once 50% to 80%, has fallen to about 4.5% — largely deaths from comorbid disease — which is why recognition before the airway fails is the nursing payload of this page.

The crisis cascade: a trigger unmasks bulbar weakness, then respiratory-muscle weakness, then a falling FVC and NIF — the nurse acts on the trend; gas-exchange numbers lag the bedside decline.

Causes & risk factors

Modifiable factors are teaching targets — the patient can act on them.

Anti-AChR antibodies — present in about 80–85% of generalized MG but only ~50% of purely ocular MG Anti-MuSK (about 5–10%) or anti-LRP4 antibodies; seronegative on standard assays in the remainder Thymic hyperplasia (about two-thirds of patients) or thymoma (about 10%) Bimodal onset — women under 40, men over 50 Coexisting autoimmune disease (about 10%; thyroid disease screened at diagnosis) Drug-induced MG — D-penicillamine (1–7% of users, usually mild and ocular) and immune checkpoint inhibitors (rare, but severe with a high rate of respiratory crisis) Infection — a leading crisis trigger, especially respiratory infection modifiable Surgery, anesthesia, and neuromuscular-blocking agents modifiable Pregnancy and especially the first months postpartum Emotional or physical stress, pain, sleep deprivation, fatigue modifiable Heat and temperature extremes, fever modifiable Medication changes — starting high-dose corticosteroids, tapering immunotherapy, or adding a drug that impairs transmission (aminoglycosides, fluoroquinolones, macrolides, beta-blockers, magnesium) modifiable Aspiration from bulbar weakness (itself a crisis precipitant) modifiable

Signs & symptoms

Each finding tied to the mechanism that produces it — and the triage it calls for.

Ptosis and diplopia — the first symptoms in about 85% early Expected
Why: The levator palpebrae and extraocular muscles fire continuously and have a low safety factor, so they fatigue first; the lids droop and the eyes lose alignment. Ptosis worsens with sustained upgaze — the bedside fatigability test.
Weakness that is worse late in the day and after repetitive use, better after rest or sleep Expected
Why: Each repeated impulse releases less ACh onto a depleted receptor field, so more fibers fail with use; rest lets release recover. This fluctuating, fatigable pattern is the disease’s signature.
Expressionless face, the "myasthenia snarl" on smiling, jaw propped up by a hand Expected
Why: Facial and masticatory muscles weaken with use, so chewing tires as a meal goes on and patients may support the chin by hand.
Dysarthria, nasal or staccato speech, hoarseness Hold & notify
Why: Bulbar (laryngeal, palatal, tongue) weakness — the initial presentation in about 15%. A new nasal quality to speech is a heralding cue of impending crisis.
Dysphagia, choking on liquids, nasal regurgitation, difficulty chewing Hold & notify
Why: Oropharyngeal muscles cannot clear the bolus or seal the nasopharynx — a high aspiration risk and one of the strongest heralds of respiratory failure. New or worsening dysphagia: NPO, aspiration precautions, notify now.
Proximal limb weakness (arms more than legs) and head drop Expected
Why: Proximal and neck-extensor muscles are preferentially affected; the neck extensors fatigue until the head falls forward. Improves after rest.
Spread beyond the eyes — bulbar, axial, and limb involvement late
Why: Ocular-onset disease becomes generalized in about 50% within two years; early immunosuppression lowers that risk (36% untreated vs 7% on prednisone in one series).
Weak cough, cannot count to 15 on a single breath, loss of gag Hold & notify
Why: Expiratory muscle weakness. Inability "to count to 15 or more during the expiratory phase of a single full capacity breath" and "diminished cough strength" are listed neuromuscular signs of impending respiratory failure — airway clearance is failing, the aspiration and atelectasis setup.
Dyspnea with accessory-muscle use, paradoxical breathing, orthopnea, diaphoresis late Report immediately
Why: The diaphragm and intercostals have failed and the neck muscles are recruited to breathe — myasthenic crisis may be close. This is a respiratory emergency: "early intubation is needed for most patients," and elective intubation is favored over crash intubation.
Pupils, deep tendon reflexes, and sensation normal
Why: The lesion is at the postsynaptic membrane, not the nerve or CNS. Contrast: Guillain-Barré brings distal paresthesias and absent reflexes; multiple sclerosis brings hyperreflexia, spasticity, and a positive Babinski; Lambert-Eaton weakness improves with exercise.
Miosis, drooling, bronchorrhea, diarrhea, bradycardia, fasciculations in a weak patient Report immediately
Why: MG itself spares the autonomic system, so muscarinic signs in a weak myasthenic point to cholinergic excess from the anticholinesterase, not to MG. Hold the drug, protect the airway, notify — atropine treats the muscarinic signs but not the weakness.
Fluctuating course — exacerbations and remissions Expected
Why: Antibody titers, receptor turnover, and triggers (infection, heat, stress, sleep loss, drug changes) shift the balance at the junction; remissions occur but are rarely permanent.

Diagnostics

Test In this disorder Normal
Serum antibodies — anti-AChR, then anti-MuSK, then anti-LRP4 / cell-based assay First-line and specific — a positive result confirms MG. A negative standard assay does not exclude it (seronegative MG); anti-striational antibodies (about 30%) flag possible thymoma Anti-AChR positive in ~80–85% of generalized and ~50% of ocular MG; if negative → anti-MuSK (5–10%); if both negative → anti-LRP4 or a cell-based assay StatPearls Undetectable
Repetitive nerve stimulation (RNS) Hold anticholinesterase drugs for at least 12 hours before the study or the result is falsely normal; limb warmed to 35 °C; most sensitive in facial muscles. Lambert-Eaton shows the opposite — an incremental response (≥ 100%) with fast-rate stimulation Decrement > 10% in compound muscle action potential amplitude between the first and fourth or fifth response at slow-rate (2–5 Hz) stimulation StatPearls No significant decrement
Single-fiber EMG (SFEMG) The most sensitive diagnostic test for MG, but abnormal jitter is not specific to MG Increased jitter — impaired neuromuscular transmission StatPearls Normal jitter
Ice-pack test (bedside, ptosis only) Cooling lowers acetylcholinesterase activity, so ACh persists longer at the junction. Specificity ~97% but sensitivity as low as 38.5% on a single test (73% with repetition) — a positive test is convincing, a negative excludes nothing; it cannot assess the extraocular muscles and is not the primary diagnostic approach ≥ 2 mm improvement in ptosis after ice is held over the closed eye for 2–5 minutes = positive Marinos et al. 2018 (Eye) —
Edrophonium (Tensilon) test — the historical exam answer Obsolete in the US: edrophonium was discontinued by the FDA in 2018 over safety and false-positive concerns, and guidelines say it should not be the primary diagnostic approach. It has been replaced by antibody testing and electrodiagnostics — and it is not how myasthenic and cholinergic crises are told apart today A short-acting IV anticholinesterase transiently improved strength in MG (historical sensitivity 71–95%) FDA discontinuation 2018 (as reported by Keritam et al. 2026) —
Chest CT (or MRI) — thymoma screen A thymoma changes management (all thymomas are resected). Purely ocular disease also gets brain/orbit MRI to exclude a structural mimic. In pregnancy, non-contrast CT is safe but is preferably postponed until after delivery Mandatory in every newly diagnosed patient; thymic hyperplasia or thymoma StatPearls; International Consensus Guidance 2016 —
Bedside forced vital capacity (FVC) and negative inspiratory force (NIF) Measure serially — trend beats snapshot. In MG, vital capacity "correlates less well to the need of mechanical ventilation than in other neuromuscular disorders," so bulbar decline, accessory-muscle use and a weak cough weigh as much as the number. The 20/30/40 rule comes from the Guillain-Barré/neuromuscular literature; no MG guideline sets these thresholds Neuromuscular respiratory-failure criteria (the "20/30/40 rule"): "Vital lung capacity <20 mL/kg, or a maximal inspiratory pressure <30 cm H2O, or a maximal expiratory pressure <40 cm H2O" StatPearls Guillain-Barré chapter (neuromuscular criteria); Gilhus 2023 (J Neurol) Adult vital capacity about 3–5 L
Arterial blood gas The intubation decision is made on bedside strength and the FVC/NIF trend, not the gas — by the time PaCO₂ rises, those criteria have usually already been met, so a normal reading is not reassurance. Also at diagnosis: ANA, rheumatoid factor, thyroid function (autoimmune comorbidity), and CBC/LFTs before azathioprine The neuromuscular intubation criteria carried by the Guillain-Barré literature list PaCO₂ > 48 mm Hg or PaO₂ < 56 mm Hg — not MG-specific thresholds StatPearls Guillain-Barré chapter (neuromuscular criteria) —

Complications

Warning: Myasthenic crisis — respiratory failure Report immediately
Worsening weakness that requires intubation or noninvasive ventilation. Heralds: new dysphagia, nasal speech, nasal regurgitation, weak cough, cannot count to 15, accessory-muscle use, orthopnea, paradoxical breathing, diaphoresis.
Affects 15–20% of patients at least once; most need early intubation, favoring elective over emergent. Mortality is now about 4.5%. Act on the bedside trend, not the gas — the neuromuscular criteria put vital capacity < 20 mL/kg and inspiratory force weaker than −30 cmH₂O in intubation range. Management: airway, hold or sharply reduce the anticholinesterase (ChEIs "increase airway secretions, which may exacerbate breathing difficulties"), PLEX or IVIG, treat the trigger, and aggressive chest physiotherapy and suctioning to prevent atelectasis.
Warning: Cholinergic crisis — too much anticholinesterase Report immediately
Muscarinic flood (salivation, lacrimation, urination, diarrhea, GI cramping, emesis, miosis, bronchorrhea, bradycardia) plus nicotinic fasciculations and flaccid weakness of the respiratory muscles.
Rare — "cholinergic crises are now rare" — but life-threatening: death comes from progressive respiratory failure. The textbook contrast (myasthenic = tachycardia, pale cool skin, no GI change; cholinergic = bradycardia, red warm skin, diarrhea, secretions) is a recognition aid, not the decision point: professional guidance treats both the same — airway first, hold the drug, PLEX/IVIG — and adds atropine 2 mg IV, repeated to atropinization, for the muscarinic signs. Atropine does nothing for the weakness, so ventilatory support still stands.
Warning: Aspiration → pneumonia → crisis Hold & notify
Dysphagia and a lost gag carry a high aspiration risk; aspiration pneumonitis is itself a crisis precipitant, and respiratory tract infections "can lead to MG exacerbations and precipitate an MG crisis."
A vicious loop: bulbar weakness → aspiration → infection → more weakness. New choking, nasal regurgitation, or a wet voice means NPO, upright, suction at the bedside, notify. On the ventilator, anticholinesterase drugs are held partly because they increase airway secretions.
Caution: Transient worsening when corticosteroids start Hold & notify
Weakness deepens in 25–75% of patients after a high-dose steroid start, mostly within the first two weeks, and can precipitate crisis.
Risk is highest in older, generalized, bulbar, and severe disease. Mitigation: start low and titrate (e.g., 10 mg/day, up by 10 mg every 5–7 days) or give PLEX/IVIG first and let it take hold before steroids begin. Early worsening does not predict a poor eventual response — most improve within 2–3 weeks. Watch swallow and breathing closely in the first fortnight.
Caution: The price of long-term immunosuppression
Steroids: osteoporosis, hyperglycemia, cataracts, weight gain, hypertension, avascular necrosis, cushingoid change. Immunosuppressants: opportunistic infection (fungal, TB, PCP) and lymphoproliferative malignancy.
Long-term immunosuppression is usually necessary, so surveillance is lifelong: azathioprine needs WBC and liver function monitoring (leukopenia and hepatotoxicity); mycophenolate and methotrexate are teratogenic and contraindicated in pregnancy. Infection prevention — handwashing, yearly influenza vaccine — is doubly important because infection is also a leading crisis trigger.

Medications for this condition

Why each class is prescribed here — every card links to its full pharmacology page.

Cholinergic Agonists First-line
Autonomic · bethanechol

The first-line symptomatic therapy — pyridostigmine should initiate most treatment regimens. As an anticholinesterase it raises the level and duration of ACh at the junction so the surviving receptors are stimulated more; onset 15–30 min, duration 3–4 h, so doses are scheduled through the day, given exactly on time and about one hour before meals so peak strength coincides with chewing and swallowing. Extended-release tablets are swallowed whole; a missed dose is never doubled. Its adverse effects are muscarinic excess — cramping, loose stools, sweating, drooling — and overdose is cholinergic crisis. Two exam rules: MuSK patients respond poorly and get side effects at usual doses, and during crisis or ventilation the drug is held or sharply reduced, never added, because it increases airway secretions.
Corticosteroids First-line
Endocrine · prednisone

The first-line immunosuppressant when pyridostigmine alone does not meet goals, and the initial immunosuppressive agent of choice in ocular MG (it also cuts generalization). Benefit begins within days and most patients improve within 2–3 weeks; prednisone is the immunosuppressant of choice in pregnancy. The disorder-specific hazard is transient worsening in 25–75% when high doses start — so the dose is titrated up slowly or PLEX/IVIG is given first, and swallow and breathing are watched for the first two weeks. Many patients need long-term low-dose maintenance; taper once goals are met.
Immunosuppressants / Biologics / DMARDs
Immune / Anti-infective · methotrexate

The steroid-sparing layer — used alone when steroids are contraindicated or refused, started alongside steroids when steroid risk is high, or added when steroids fail, cause side effects, or cannot be tapered. Azathioprine is the first-line steroid-sparing agent but takes 12–18 months for full effect (monitor WBC and liver tests); mycophenolate, methotrexate, cyclosporine, and tacrolimus are alternatives with weaker evidence. Adjust no more often than every 3–6 months; mycophenolate and methotrexate are contraindicated in pregnancy. Rituximab is an early option in MuSK-MG that fails initial therapy.

Beyond medications

  • Thymectomy — mandatory for every thymoma (complete resection); recommended early — within about two years of onset — for non-thymomatous AChR-antibody-positive generalized MG aged 18–50 to improve outcomes and cut immunotherapy needs (International Consensus Guidance 2020). In the MGTX trial it lowered weakness scores, halved alternate-day prednisone requirements (32 vs 54 mg), and reduced crisis admissions. Not indicated in MuSK, LRP4, or agrin-antibody disease, and generally not in purely ocular MG. It is elective — done when the patient is stable, after preoperative optimization with anticholinesterases, PLEX, or IVIG, because benefit is delayed (visible from 3–4 months) and postoperative myasthenic crisis is a recognized risk. Minimally invasive approaches (VATS, robotic, transcervical) perform as well as sternotomy.
  • IVIG or plasma exchange (PLEX) — the rapid-acting rescues for crisis, impending crisis, dysphagia, preoperative preparation, and cover before a steroid start. Probably equally effective; "expert consensus suggests that PLEX is more effective and works more quickly," and it may be more effective in MuSK-MG. PLEX is avoided in sepsis and hemodynamic instability and needs special venous access (watch for hypocalcemic paresthesias and transient hypotension); IVIG is avoided in hypercoagulable states, renal failure, and IgA deficiency (anaphylaxis), and can cause headache, aseptic meningitis, thrombosis, and renal injury.
  • Crisis supportive care — ICU-level respiratory and bulbar monitoring; elective intubation on the bedside trend; respiratory support "can in some patients begin with non-invasive positive-pressure ventilation," but most need early intubation because of aspiration risk. On the ventilator: lung-protective settings to prevent atelectasis, aggressive chest physiotherapy and suctioning; weaning follows recovering strength, and a weak cough and poor airway clearance are the usual reasons extubation fails. Treat the trigger aggressively — including infection, while steering around the antibiotics that worsen MG.
  • Biologics for refractory disease — rituximab early in MuSK-MG that fails initial immunotherapy (minimal-manifestation status in 72% of MuSK vs 30% of AChR patients); eculizumab or ravulizumab (complement C5 inhibitors that block the membrane attack complex) for severe refractory AChR-positive generalized MG, with meningococcal vaccination at least 2 weeks before starting; FcRn inhibitors (efgartigimod, rozanolixizumab, nipocalimab) lower circulating IgG as later-line therapy. Maintenance IVIG or PLEX is an option when nothing else holds.
  • Rehabilitation and allied health — physical, occupational, and speech therapy plus a dietitian for patients who struggle to swallow and eat; vocational rehabilitation for home and work modification (raised toilet seat, handrails).
  • Lifestyle and self-protection — balance activity with rest periods and plan demanding tasks for times of peak strength, avoid temperature extremes and emotional stress, use an eye patch as needed, handwashing and a yearly influenza vaccine, a medical identification bracelet, and clearance with the provider before any new medication. Pregnancy is planned with the disease optimized beforehand; most well-controlled women stay stable, with worsening most likely in the first postpartum months.

Nursing considerations

The RN-specific layer — each action paired with the reason it matters.

Assessment & monitoring
Assess voluntary muscle strength and fatigability — sustained upgaze for ptosis, repeated movements, then recovery with rest — along with the patient’s ability to complete daily activities.
Why: MG is defined by weakness that worsens with repetition and recovers with rest; a strength score taken once, at rest, misses the disease. Function tells you the severity.
Run serial bedside FVC and NIF, the single-breath count, and watch for accessory-muscle use, paradoxical breathing, orthopnea, diaphoresis, nasal speech, and a weak cough — trend them, and escalate as vital capacity approaches 20 mL/kg or inspiratory force weakens toward −30 cmH₂O.
Why: Respiratory-muscle failure is the way MG kills, and the bedside numbers fall before SpO₂ or PaCO₂ move. Elective intubation on trajectory beats a crash intubation; expiratory and inspiratory forces are more sensitive than VC alone.
Monitor swallowing at every meal — choking, coughing after liquids, nasal regurgitation, a wet or nasal voice, and the gag — and monitor vital signs.
Why: Bulbar weakness is both the leading aspiration risk and the herald of impending crisis; aspiration pneumonitis then becomes the next trigger.
Screen for muscarinic signs — miosis, drooling, bronchorrhea, diarrhea and cramping, bradycardia, sweating, fasciculations — especially after a dose change.
Why: MG spares the autonomic system, so these signs in a weak patient point to cholinergic excess from the anticholinesterase. Recognize the pattern, but remember the action is the same either way: airway, hold the drug, notify.
In the first two weeks after a high-dose corticosteroid start, tighten swallow and respiratory surveillance.
Why: Transient steroid-induced worsening occurs in 25–75% of patients, mostly in the first two weeks, and has precipitated crisis — the drug that will help next month can hurt this week.
Track immunosuppression labs — WBC and liver function on azathioprine — and assess for infection, fever, and skin breakdown; reposition frequently and assess fall risk.
Why: Leukopenia and hepatotoxicity are the serious azathioprine effects; infection is a leading crisis trigger; weakness and fatigue make falls and pressure injury likely.
Interventions & crisis safety
Give pyridostigmine exactly on time, timed about one hour before meals; never crush extended-release tablets; use the IV route only if ordered when the patient cannot swallow.
Why: A late dose means a weak patient — delays exacerbate weakness — and onset of 15–30 minutes with a 3–4 hour duration means meals must sit inside the peak for safe chewing and swallowing.
Aspiration precautions: sit fully upright to eat, chin down when swallowing, small frequent meals of soft, high-calorie food scheduled at peak drug effect; keep suction and emergency airway equipment at the bedside.
Why: Oropharyngeal weakness cannot clear a bolus; the chin-down posture protects the airway and the meal timing borrows the drug’s strongest hour.
When impending crisis is recognized — new dysphagia, nasal speech, weak cough, falling FVC/NIF — make the patient NPO, raise the head of the bed, notify the provider now with the trend, and anticipate ICU transfer, an elective airway plan, and PLEX or IVIG.
Why: Most crisis patients need early intubation, and elective intubation is favored over emergent; waiting for a saturation drop or an ABG is waiting for failure.
In crisis, hold or sharply reduce the anticholinesterase per order — never give an extra dose to "boost" the patient — and give atropine for muscarinic signs; do not expect an edrophonium test.
Why: Anticholinesterases increase airway secretions and confound assessment regardless of which crisis it is; atropine blocks the muscarinic flood but not the weakness; edrophonium is no longer available in US practice.
Screen every new order against the MG drug-avoidance list — aminoglycosides, fluoroquinolones, macrolides, beta-blockers, calcium channel blockers, magnesium (IV, antacids, laxatives), botulinum toxin, class Ia antiarrhythmics, phenytoin, checkpoint inhibitors, D-penicillamine — and flag neuromuscular blockers before any procedure.
Why: Each impairs transmission at an already-failing junction; azithromycin was the drug most often linked to deterioration in one series of MG exacerbations. Patients are resistant to succinylcholine and highly sensitive to nondepolarizers — reduced doses are required.
Plan care in short blocks that coincide with maximal strength, cluster activities, and enforce rest periods; provide artificial tears by day and an eye patch as needed.
Why: Fatigue can itself trigger crisis; an eye patch abolishes diplopia and protects a cornea the lid cannot close over.
Patient & family teaching
Take pyridostigmine exactly as prescribed and on time, about an hour before meals; never more, never less, never doubled after a missed dose; swallow extended-release tablets whole.
Why: Stable drug levels keep the junction working; a missed dose weakens the patient, an extra dose risks cholinergic crisis. Difficulty breathing, slurred speech, confusion, or seizures after dosing means call for help.
Recognize and avoid triggers — infection (handwashing, yearly influenza vaccine, keep vaccinations current), heat and temperature extremes, emotional stress, fatigue, surgery — and report fever early.
Why: Infection is a leading crisis trigger; rest and trigger avoidance are the patient’s own crisis prevention.
Carry a medication-avoidance card and wear a medical identification bracelet; tell every prescriber, dentist, ophthalmologist, and pharmacist about MG; check with the provider before any new drug, including magnesium-containing antacids and laxatives.
Why: Many common drugs — certain antibiotics, beta-blockers, calcium channel blockers, magnesium, statins — can unmask or worsen weakness, and an unconscious patient cannot warn the anesthesiologist about neuromuscular blockers.
Teach the emergency plan: worsening breathing or swallowing can be a myasthenic crisis, which "requires immediate emergency medical care"; agree an "emergency code" with family (such as ringing the phone twice) for when the patient is too weak to speak; family learns CPR, the Heimlich maneuver, and how to activate EMS.
Why: Crisis can arrive within days of the first bulbar symptom, and a patient in crisis may be unable to call for help in words.
Pace the day: balance activity with rest periods, schedule demanding tasks at peak strength, use an eye patch for double vision, and keep regular follow-up with a neurologist familiar with MG plus annual health screening.
Why: Remissions are rarely permanent and relapse risk persists; energy planning reduces the fatigue that precipitates exacerbations, and autoimmune comorbidities need surveillance.
In pregnancy: optimize control before conception; oral pyridostigmine and prednisone are the drugs of choice; magnesium sulfate is not used for preeclampsia and IV anticholinesterases are avoided; expect the newborn to be observed in hospital for at least 3 days for transient neonatal MG.
Why: Magnesium blocks neuromuscular transmission and has caused crisis; maternal IgG crosses the placenta, so 10–20% of newborns show transient hypotonia, weak cry, and feeding difficulty — often delayed 6–72 hours — regardless of how well the mother is controlled.

How a real nurse thinks

The clinical-judgment loop, worked for a typical presentation — reasoning, not reference.

  1. 1
    Recognize cues

    The cues that matter are the bulbar and respiratory heralds appearing over hours in a patient with a known trigger: new dysphagia with nasal regurgitation, nasal speech, a weak cough, counting only to 11 on one breath, accessory-muscle breathing, and an FVC that fell from 40 to 22 mL/kg with an NIF weakening from −40 to −24 cmH₂O in ten hours — all riding on a febrile respiratory infection, a leading crisis trigger. The noise: SpO₂ 96% and a clear chest X-ray. Note what is absent: no miosis, no drooling, no diarrhea, no bradycardia, no fasciculations — and the doses have been on time, not extra.

  2. 2
    Analyze cues

    This is impending myasthenic crisis — rapid worsening that could need ventilation within days or hours — unmasked by infection. The pattern argues myasthenic rather than cholinergic: an obvious trigger, scheduled dosing without extras, and no muscarinic signs. But the analysis must end with the professional rule: the distinction does not change the first actions — the airway comes first and pyridostigmine is held either way, and no edrophonium test is coming to settle it. The 96% saturation is the trap: the intubation criteria are bedside-first, and the FVC/NIF trend has already crossed into the range where intubation is discussed — gas-exchange numbers lag that decline. One more cue has teeth: the pending azithromycin order — a macrolide, the drug most often linked to deterioration in one series of MG exacerbations.

  3. 3
    Prioritize

    The threat is loss of the airway — by aspiration tonight or by diaphragm failure in the next hours. Priority one is therefore airway protection and escalation: NPO, upright, suction at hand, and the provider or rapid-response team called with the numbers now. Priority two is removing what will make it worse: the azithromycin order is held pending clarification, and no extra pyridostigmine is given to "boost" her. The fever and the WBC of 12.8 matter — the infection still has to be treated — but with an antibiotic that does not impair transmission. Documentation and the routine 2000 medication pass come after the patient is safe.

  4. 4
    Generate solutions

    Options: (1) keep her on the floor with two-hourly checks and see how the 2000 dose goes — rejected, because most crisis patients need early intubation and elective is safer than emergent; (2) escalate now with an SBAR that leads with the FVC/NIF trend, anticipating ICU transfer, an elective airway plan, PLEX or IVIG, holding or reducing pyridostigmine, and a non-worsening antibiotic — chosen; (3) give an extra pyridostigmine dose for the weakness — rejected, because it adds secretions to a failing airway and risks cholinergic crisis; (4) draw an ABG first and act on the result — rejected as the deciding step, because a rising PaCO₂ means she has already failed.

  5. 5
    Take action

    Act, then call: NPO, head of bed up, suction and airway equipment at the bedside, continuous pulse oximetry, hold the 2000 azithromycin. Then the SBAR: "34-year-old with generalized MG admitted with a URI, now febrile 38.1 with new dysphagia and nasal regurgitation, nasal speech, weak cough, counting to 11, accessory-muscle use. FVC has fallen from 2.4 L to 1.3 L — 22 mL/kg — and NIF from −40 to −24 in ten hours. SpO₂ is still 96%. I have made her NPO and held the new azithromycin because macrolides worsen MG. Requesting immediate evaluation — anticipate ICU transfer, elective airway planning, PLEX or IVIG, and guidance on the pyridostigmine." The trap avoided: reading a normal saturation as reassurance, or giving more pyridostigmine because "she is weak."

  6. 6
    Evaluate

    Success over the next hours: ICU-level monitoring with serial FVC/NIF; PLEX or IVIG started (PLEX usually acts faster); pyridostigmine held or reduced per order; an antibiotic that does not impair transmission; no aspiration event. If vital capacity keeps falling below 20 mL/kg or inspiratory force cannot pull past −30, the airway is secured electively — before the ABG turns. Recovery is judged the same way the crisis was: strength and vital capacity climbing back before weaning, a cough strong enough to clear secretions, and oral pyridostigmine restarted just before or after extubation.

Scenario — you’re the nurse

Work each question before revealing the answer. Rationales explain the wrong options too.

Medical unit · 1830, hospital day 2

A 34-year-old woman with AChR-antibody-positive generalized MG (MGFA Class IIb), on scheduled pyridostigmine and low-dose prednisone, admitted yesterday with an upper respiratory infection and a productive cough. Weight 60 kg. This morning she was ambulating and eating a regular diet. At dinner she choked on water, and some came back through her nose. She tells you, with a nasal, breathy voice: "I feel weaker than this morning."

1830 vitals — HR 104 · BP 142/86 · RR 24 · SpO₂ 96% on room air · T 38.1 °C
Assessment — bilateral ptosis worse than at 0800 · nasal speech · weak, ineffective cough · counts to 11 on one breath · using sternocleidomastoids to breathe · lungs clear · pupils equal and normal size · no drooling, no diarrhea, no cramping · reflexes and sensation intact
Bedside respiratory — 0800: FVC 2.4 L (40 mL/kg) · NIF −40 cmH₂O → 1830: FVC 1.3 L (22 mL/kg) · NIF −24 cmH₂O
Meds — pyridostigmine given on schedule, last dose 1600 · prednisone unchanged · new 1700 order: azithromycin for bronchitis, first dose due 2000, not yet given
Labs — WBC 12.8 · no ABG drawn · chest X-ray this morning: no infiltrate
Q1 Select all that apply
Which findings indicate impending myasthenic crisis and require immediate escalation? Select all that apply.
  1. A. Nasal speech and nasal regurgitation of water at dinner
  2. B. FVC falling from 40 mL/kg to 22 mL/kg over ten hours
  3. C. Weak cough and counting only to 11 on one breath
  4. D. SpO₂ 96% on room air
  5. E. Pupils equal and of normal size
Reveal answer & rationale
Answer: A, B, C
New bulbar weakness (A) and failing expiratory strength (C) are the documented heralds of respiratory failure, and an FVC trending toward 20 mL/kg with a weakening NIF (B) is the range in which elective intubation is discussed — all three demand escalation now. A saturation of 96% (D) is the trap: the intubation criteria are bedside-first — strength and the FVC/NIF trend — so a normal saturation does not exclude impending failure. Normal pupils (E) are expected in MG — the disease spares the autonomic system — and their normality simply argues against cholinergic excess; they are not an escalation cue.
Q2 Multiple choice
The 2000 azithromycin dose for the patient’s bronchitis is due. The best nursing action is to:
  1. A. Give it as ordered — treating the infection is the priority in crisis prevention
  2. B. Give it with a dose of pyridostigmine to offset any weakness
  3. C. Hold it and contact the prescriber, because macrolides can worsen myasthenia gravis and an alternative is needed
  4. D. Hold all antibiotics until the neurologist has seen the patient
Reveal answer & rationale
Answer: C
Macrolides — azithromycin especially — impair neuromuscular transmission, and azithromycin was the drug most often linked to deterioration in one series of MG exacerbations; aminoglycosides and fluoroquinolones share the warning. The rule is to avoid them where possible while still treating the infection aggressively with a safer agent, so hold and clarify (C). Giving it (A) adds a second trigger on top of the infection. Adding pyridostigmine (B) floods a failing airway with secretions and risks cholinergic crisis. Holding all antibiotics (D) leaves a leading crisis trigger untreated.
Q3 Multiple choice
A colleague says, "We need to figure out whether this is a myasthenic or a cholinergic crisis before we do anything." Which response reflects current management?
  1. A. "Yes — ask the provider for an edrophonium test; improvement means myasthenic, worsening means cholinergic."
  2. B. "Her skin is warm and she is tachycardic, so it is myasthenic — give an extra pyridostigmine dose."
  3. C. "The first actions are the same either way: protect the airway, hold the pyridostigmine, and prepare for PLEX or IVIG — atropine is added only if she shows muscarinic signs."
  4. D. "Give atropine now to be safe; it treats both kinds of crisis."
Reveal answer & rationale
Answer: C
Professional guidance treats the two crises identically at the bedside — airway first, hold or reduce the anticholinesterase, PLEX or IVIG — because the distinction is unreliable and cholinergic crisis is rare with modern dosing; atropine is reserved for muscarinic signs (C). Edrophonium (A) is the classic exam answer but was discontinued by the FDA in 2018 and is not primary practice. Skin temperature and heart rate (B) are a nursing-textbook recognition aid, not a decision point — and an extra dose is exactly the wrong move. Atropine (D) blocks muscarinic effects only; it does nothing for weakness and is not indicated without muscarinic signs.
Q4 Put in order
Put the nurse’s first four actions in priority order:
  1. A. Notify the provider or rapid-response team with the FVC/NIF trend, anticipating ICU transfer and PLEX or IVIG
  2. B. Make the patient NPO, raise the head of the bed, and bring suction and airway equipment to the bedside
  3. C. Hold the 2000 azithromycin and request an alternative antibiotic
  4. D. Document the assessment, the trend, and the notifications
Reveal answer & rationale
Correct order: B → A → C → D
The immediate hazard is aspiration and airway loss, so the no-order-needed protections come first (B). Escalation with the numbers follows at once (A) — most crisis patients need early intubation, and elective beats emergent. The azithromycin is not due until 2000, so holding it and requesting an alternative (C) rides along with the SBAR rather than preceding the call. Documentation (D) never comes before the patient is safe. Calling first (A) leaves a choking patient without suction at hand while you are on the phone.
Q5 Multiple choice
The patient is transferred to the ICU and plasma exchange is started. Her sister asks, "Why did they stop her myasthenia pill? Isn’t that the medicine that makes her stronger?" The best response is:
  1. A. "It was stopped because plasma exchange removes it from her blood, so it would be wasted."
  2. B. "During a crisis the pill increases airway secretions and can make breathing harder, so it is held or reduced and restarted once she is stronger, around the time the breathing tube comes out."
  3. C. "It was stopped permanently — the plasma exchange replaces it."
  4. D. "It was causing the crisis, which is why she got weaker."
Reveal answer & rationale
Answer: B
Anticholinesterases are held or sharply reduced during crisis regardless of type because they increase pulmonary secretions in a patient already struggling to breathe, and they are restarted just before or after extubation once strength has clearly improved (B). PLEX does not "waste" the drug (A); it removes circulating antibodies. Pyridostigmine remains the long-term symptomatic therapy, so (C) is false. Nothing in this case points to cholinergic crisis — doses were on schedule and muscarinic signs were absent — so (D) misreads the trigger, which was the infection.

Common questions

What causes myasthenia gravis?
Common causes and risk factors include anti-achr antibodies — present in about 80–85% of generalized mg but only ~50% of purely ocular mg, anti-musk (about 5–10%) or anti-lrp4 antibodies; seronegative on standard assays in the remainder, thymic hyperplasia (about two-thirds of patients) or thymoma (about 10%), bimodal onset — women under 40, men over 50, coexisting autoimmune disease (about 10%; thyroid disease screened at diagnosis), and others.
What are the early signs of myasthenia gravis?
Early findings include Ptosis and diplopia — the first symptoms in about 85%.
Which findings should a nurse report immediately in myasthenia gravis?
Report immediately: Dyspnea with accessory-muscle use, paradoxical breathing, orthopnea, diaphoresis, Miosis, drooling, bronchorrhea, diarrhea, bradycardia, fasciculations in a weak patient, Myasthenic crisis — respiratory failure, Cholinergic crisis — too much anticholinesterase. These signal deterioration that needs rapid intervention.
How is a myasthenic crisis different from a cholinergic crisis — and does it change what the nurse does?
A myasthenic crisis is the disease overwhelming the junction — usually after a trigger like infection, surgery, a steroid start, or a worsening drug — until the respiratory muscles fail. A cholinergic crisis is too much anticholinesterase: the same flaccid weakness plus muscarinic signs — miosis, drooling, bronchorrhea, diarrhea and cramping, bradycardia, fasciculations. The textbook table (tachycardia and pale skin versus bradycardia and flushed skin) is a recognition aid, and the old edrophonium test is no longer available in the US. Current guidance manages both the same way: secure the airway, hold or reduce the anticholinesterase, give PLEX or IVIG, and add atropine only for muscarinic signs — atropine does nothing for the weakness itself.
Why is the Tensilon (edrophonium) test no longer the answer?
Edrophonium, a short-acting IV anticholinesterase, transiently improved strength in MG and was once used both to diagnose the disease and to "sort" crises. The FDA discontinued it in 2018 over safety and false-positive concerns, and guidelines say it should not be the primary diagnostic approach. Diagnosis now rests on antibody testing (anti-AChR in about 80–85% of generalized disease, then anti-MuSK, anti-LRP4, or cell-based assays), repetitive nerve stimulation (a decrement over 10%), and single-fiber EMG (the most sensitive test) — plus the bedside ice-pack test for ptosis, which is highly specific but misses many cases. Every new patient also gets a chest CT for thymoma.
Why must pyridostigmine be given exactly on time and about an hour before meals?
Pyridostigmine works by keeping more acetylcholine at the junction, but it starts working in 15–30 minutes and wears off in 3–4 hours — so a late dose leaves the patient weak, and delays can exacerbate weakness. Giving it about one hour before meals puts chewing and swallowing inside the drug’s peak, which is the single best aspiration precaution a schedule can buy. The flip side: never double a missed dose or add an extra one for "boosting" — too much drug produces muscarinic side effects and, at the extreme, cholinergic crisis. During a crisis the drug is held, because it increases airway secretions.

Sources

Reviewed by Hae Suk Lee, RN

Educational summary for nursing students. Scenarios are fictional teaching cases. Always verify against current guidelines and your institution's protocols before acting in practice. Not medical advice.

Bookmark LearnDrugs.com?

Your saved pages are kept in this browser. Add LearnDrugs.com to your browser’s bookmarks to get back to them in one click.

Drag this link to your bookmarks bar: LearnDrugs.com

Or press Ctrl + D to bookmark the page you’re on.